Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc. a clinical-stage biotechnology company engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers as well as refractory and relapsed pediatric and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development wound healing and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals Inc. and changed its name to Provectus Biopharmaceuticals Inc. in December 2013. Provectus Biopharmaceuticals Inc. was founded in 2002 and is based in Knoxville Tennessee.